SARS-CoV-2 Spike D614G mutant Cell Line from Innoprot stable expresses SARS-CoV-2 Spike Glycoprotein encoding a D614G mutation. Coronaviruses (CoVs) infect human and animals and cause varieties of diseases, such as respiratory, enteric, renal, and neurological diseases. At the end of 2019, a novel coronavirus, named SARS-CoV-2, was found in patients with severe pneumonia in Wuhan, China. It is is now spreading across the globe. A SARS-CoV-2 variant carrying the Spike protein amino acid change D614G has become the most prevalentform in the global pandemic. G614 mutation shows potentially higher viral loads in COVID-19 patients.
SARS-CoV-2 uses its spike glycoprotein (S), a main target for neutralization antibody, to bind its receptor, and mediate membrane fusion and virus entry. It uses hACE2 to enter cells, correlating with the efficient spread of SARS-CoV-2 among humans. S comprises two functional subunits responsible for binding to the host cell receptor (S1 subunit) and also fusion of the viral and cellular membranes (S2 subunit). SARS-CoV-2 Spike Glycoprotein Cell Line cell line allows the study of SARS-CoV-2 spike/ACE2 interaction in cell-based assays.
Click here to get more information about SARS-CoV-2 Spike Glycoprotein.
Click here to get more information about D614G mutation.